Galixir

Galixir, founded in 2019, is a company that leverages globally leading artificial intelligence technology to empower drug discovery. By utilizing cutting-edge AI algorithms and integrating tools and expertise from computational chemistry, medicinal chemistry, and biology, Galixir has established a series of preclinical drug discovery models covering the entire process from drug target identification to candidate compound generation and screening, compound structure optimization, as well as drug-likeness and toxicity prediction, and patent analysis. This approach reduces the time required for the preclinical drug discovery phase, traditionally taking 4-7 years, to 12 months or even less.